Animal Models of Corticobasal Syndrome

Migration, Crosslink

📖

Animal Models of Corticobasal Syndrome

active

wiki page Created: 2026-04-02T07:19:50 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-animal-models-cbs

📖 Wiki Page

mechanism1401 wordssynced 2026-04-02

Animal Models of Corticobasal Syndrome

Overview

The development of effective therapeutics for [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS) and [Corticobasal Degeneration](/mechanisms/cbd-neuropathology) (CBD) requires reliable animal models that capture the key pathological features of this 4-repeat (4R) tauopathy. Unlike Alzheimer's disease, where amyloid and tau transgenic models have been available for decades, CBS/CBD models have only recently become available and remain imperfect representations of the human disease.

Challenges in Model Development

Key Pathological Features to Replicate

flowchart TD A["CBD Pathology to Model"] --> B["4R Tau Aggregation"] A --> C["Achromatic Balloon Neurons"] A --> D["Astrocytic Plaques"] A --> E["Coiled Bodies"] A --> F["Neuronal Loss Patterns"] A --> G["Asymmetric Cortical Atrophy"] B --> B1["Tau isoform composition"] B --> B2["Phosphorylation patterns"] D --> D1["Diffuse tau in astrocyte processes"] D --> D2["Distinct from PSP tufted astrocytes"] E --> E1["Oligodendrocyte inclusions"] E --> E2["White matter pathology"]

The challenge lies in modeling several unique features of CBD:

4R Tau Isoform Predominance: Unlike 3R/4R tauopathies (AD) or 3R tauopathies (PiD), CBD is characterized by selective accumulation of 4R tau isoforms, requiring models that express only or predominantly 4R tau.

...

Animal Models of Corticobasal Syndrome

Overview

The development of effective therapeutics for [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS) and [Corticobasal Degeneration](/mechanisms/cbd-neuropathology) (CBD) requires reliable animal models that capture the key pathological features of this 4-repeat (4R) tauopathy. Unlike Alzheimer's disease, where amyloid and tau transgenic models have been available for decades, CBS/CBD models have only recently become available and remain imperfect representations of the human disease.

Challenges in Model Development

Key Pathological Features to Replicate

Mermaid diagram (expand to render)

The challenge lies in modeling several unique features of CBD:

4R Tau Isoform Predominance: Unlike 3R/4R tauopathies (AD) or 3R tauopathies (PiD), CBD is characterized by selective accumulation of 4R tau isoforms, requiring models that express only or predominantly 4R tau.

Astrocytic Plaques: These diffuse tau-laden astrocytic processes are a hallmark of CBD but not other tauopathies, requiring astrocyte-specific targeting.

Coiled Bodies: Oligodendroglial tau inclusions are more numerous in CBD than in [PSP](/diseases/progressive-supranuclear-palsy), necessitating models that develop oligodendrocyte pathology.

Asymmetric Cortical Atrophy: CBD characteristically shows asymmetric frontoparietal atrophy, which is challenging to model in rodents with symmetric brains.

Transgenic Mouse Models

4R Tau Transgenic Models

| Model | Promoter | Mutation | Key Features | Limitations |
|-------|----------|----------|--------------|-------------|
| rTg4510 | CamKII | P301L | 4R tau expression, rapid tangle formation | Not 4R-specific, rapid progression |
| Tg4510-derived 4R | CAMKII | P301L (4R-only) | Selective 4R expression | Astrocyte pathology limited |
| hTau40-expressing | PrP | Wild-type 4R | Human 4R tau isoform | Low aggregation tendency |
| K369I transgenic | PrP | K369I | 4R tau with novel mutation | Different from CBD mutations |

The rTg4510 model, while widely used, expresses mutant human tau under the CamKII promoter and develops neurofibrillary tangles, but does not fully recapitulate the astrocytic and oligodendroglial pathology characteristic of CBD[@davey2019].

Mutation-Specific Models

P301L/P301S Models: The P301L and P301S tau mutations (found in FTDP-17) have been introduced into mice to model tau aggregation. While these models develop robust tau pathology, they predominantly form 3R/4R mixed tangles rather than the 4R-selective pathology of CBD.

MAPT Mutations: Several MAPT mutations associated with familial 4R tauopathies (e.g., S305S, P301L) have been modeled, but these typically produce PSP-like phenotypes rather than CBD-like pathology.

Astrocyte-Targeted Models

Recent efforts have focused on targeting tau expression to astrocytes to generate astrocytic plaques:

GFAP-driven 4R tau: Expression of 4R tau under the GFAP promoter induces tau accumulation in astrocyte processes
Aldh1l1-Cre models: More specific astrocyte targeting using aldehyde dehydrogenase 1L1 promoter

These models develop astrocytic tau pathology but still lack the full spectrum of CBD features[@takashima2021].

Oligodendrocyte-Targeted Models

MBP-Driven Models

Myelin Basic Protein (MBP) promoter-driven tau expression targets oligodendrocytes, allowing study of coiled body formation:

MBP-4R tau transgenics: Develop tau inclusions in oligodendrocytes resembling coiled bodies
Olig2-Cre models: Target oligodendrocyte precursor cells for tau expression

These models demonstrate that oligodendrocyte tau pathology can be induced in vivo and show white matter dysfunction similar to human CBD[@matsuura2023][@suzuki2021].

Coiled Body Pathology

The density of coiled bodies in CBD is higher than in PSP, and modeling this feature has been a focus:

Targeting oligodendrocytes with 4R tau leads to filamentous tau inclusions
Models show myelin disruption alongside tau pathology
Therapeutic targets (microtubule stabilizers, tau aggregation inhibitors) can be tested in these models

Toxin-Based Models

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

While primarily a Parkinson's disease model, MPTP in non-human primates can produce some CBS-like features:

Asymmetric parkinsonism
Cortical dysfunction
Limited utility for modeling 4R tau pathology

Cerebellin and Other Toxin Models

The neurotoxin-based approach has limited relevance for CBD since the primary pathology is tau-based rather than toxin-induced[@weller2023].

iPSC Models and In Vitro Approaches

Patient-Derived Neurons

Induced pluripotent stem cell (iPSC) models offer advantages:

Disease-relevant genetics: Patients carry risk alleles and develop pathology
Human tau isoform expression: Correct 4R:3R ratio
Cell-type specificity: Can generate neurons, astrocytes, oligodendrocytes

Recent studies using CBS patient-derived iPSCs have shown:

Increased tau phosphorylation in neurons
4R tau predominance in differentiated cells
Vulnerability of cortical neuron subtypes[@fujiwara2024]

Organoid Models

Brain organoids from CBS patients provide three-dimensional models:

Better than 2D cultures for modeling cortical architecture
Can assess network dysfunction
Limitations: lack of oligodendrocytes, incomplete maturation

Non-Human Primate Models

Advantages and Limitations

Primates offer the closest model to human CBD:

Brain structure: Larger, gyrencephalic brains with greater similarity to human
Tau isoform expression: Naturally express both 3R and 4R tau
Behavioral repertoire: More complex motor and cognitive behaviors

However, primate models face significant limitations:

Cost: Much higher than rodent models
Ethics: Increased ethical concerns
Longer lifespan: Extended development timeline
Genetic diversity: Outbred populations more similar to humans

Current Primate Models

Transgenic primates expressing mutant tau have been developed:

AAV-mediated tau expression in macaques
Transgenic rhesus monkeys with tau mutations

These models show some features of tauopathy but have not yet fully recapitulated CBD pathology[@zhang2022].

Therapeutic Testing Platforms

Preclinical Pipeline

Animal models serve critical roles in therapeutic development:

Mermaid diagram (expand to render)

Model Selection by Therapeutic Approach

| Therapeutic Approach | Preferred Model | Readouts |
|---------------------|----------------|----------|
| Anti-tau antibodies | Mouse/transgenic | Tau PET, CSF biomarkers |
| Tau aggregation inhibitors | 4R tau mice | Histology, behavior |
| Gene therapy | AAV models | Expression, efficacy |
| Cell therapy | Immune-deficient mice | Survival, integration |

Current Limitations and Future Directions

Model Gaps

No perfect model: No single model recapitulates all CBD features

Asymmetry: Rodent brains cannot model the asymmetric cortical atrophy

Astrocytic plaques: Still not fully captured in any model

Disease duration: Mouse models develop pathology over months, not years

Mixed pathologies: Most models don't include TDP-43 or AD comorbidity

Emerging Approaches

CRISPR-based models: Precise introduction of CBD-associated mutations[@chen2024]
Humanized mice: Replacing mouse tau with human tau isoforms[@singh2024]
Chimeric models: Human neurons in mouse brains[@yamamoto2025]
Multi-model approaches: Using multiple models in parallel for validation[@park2025]

Recent Research (2024-2025)

Organoid models of CBS have advanced to capture cortical architecture and network dysfunction[@nguyen2024]. Single-cell transcriptomics of CBS patient iPSC-derived neurons revealed disease-specific transcriptional signatures including dysregulation of synaptic genes, mitochondrial pathways, and tau-modifying kinases[@wang2024]. AAV-mediated tau expression in macaques demonstrated behavioral and pathological outcomes relevant to CBS, providing a non-human primate model with greater face validity[@hernandez2025].

Humanized tau mouse models expressing 4R human tau isoforms have provided improved platforms for studying CBD pathology with human-relevant tau dynamics[@singh2024]. CRISPR-based introduction of CBD-associated MAPT mutations in human iPSCs has enabled precise modeling of genetic risk factors[@chen2024].

Cryo-EM Structures from Patient-Derived Models

Cryo-EM analysis of tau filaments from patient-derived neurons has revealed structural insights unique to CBS[@takeda2024]:

CBD tau filament structure: Distinct from PSP tau filaments with different protofilament arrangements
Isoform composition: Confirmed exclusive 4R tau incorporation in CBD-derived neurons
Filament polymorphism: Multiple conformers exist within the same patient sample
Therapeutic implications: Structure-based drug design now possible for CBS-specific tau

Autophagy Dysfunction in CBS Models

Patient-derived organoids have identified autophagy impairment as a key pathogenic mechanism[@martinez2024]:

LC3-II/I ratio: Reduced in CBS patient-derived neurons indicating impaired autophagosome formation
p62 accumulation: Buildup of undegraded p62 suggests blocked autophagic flux
mTOR pathway: Constitutively active mTORC1 suppresses autophagy initiation
Therapeutic target: Autophagy enhancers (rapamycin analogs, trehalose) show efficacy in organoid models

AAV-Mediated Antibody Delivery

Gene therapy approaches using AAV delivery of anti-tau antibodies have been tested in CBS models[@liu2025]:

AAV9-blood-brain barrier: AAV9 enables transvascular delivery of anti-tau antibody fragments
Efficacy: 40-60% reduction in tau pathology in mouse models after single injection
Duration: Expression stable for 6+ months in non-human primates
Clinical translation: Phase I trial planned for CBS patients (2025)

slug	mechanisms-animal-models-cbs
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9d3619d37d7d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-animal-models-cbs'}
_schema_version	1

📗 Cite This Artifact

Animal Models of Corticobasal Syndrome

Animal Models of Corticobasal Syndrome

Overview

Challenges in Model Development

Key Pathological Features to Replicate

Animal Models of Corticobasal Syndrome

Overview

Challenges in Model Development

Key Pathological Features to Replicate

Transgenic Mouse Models

4R Tau Transgenic Models

Mutation-Specific Models

Astrocyte-Targeted Models

Oligodendrocyte-Targeted Models

MBP-Driven Models

Coiled Body Pathology

Toxin-Based Models

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Cerebellin and Other Toxin Models

iPSC Models and In Vitro Approaches

Patient-Derived Neurons

Organoid Models

Non-Human Primate Models

Advantages and Limitations

Current Primate Models

Therapeutic Testing Platforms

Preclinical Pipeline

Model Selection by Therapeutic Approach

Current Limitations and Future Directions

Model Gaps

Emerging Approaches

Recent Research (2024-2025)

Cryo-EM Structures from Patient-Derived Models

Autophagy Dysfunction in CBS Models

AAV-Mediated Antibody Delivery

See Also

💬 Discussion